|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
CN115927474A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
|
WO2016210129A1
(en)
*
|
2015-06-23 |
2016-12-29 |
Memorial Sloan-Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
|
CA2991976A1
(en)
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
EP3344656A1
(en)
|
2015-09-01 |
2018-07-11 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
EP3355920A4
(en)
|
2015-09-29 |
2019-05-15 |
Celgene Corporation |
PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
|
|
DK3356411T3
(da)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
WO2018053405A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
JP6430682B2
(ja)
*
|
2016-12-19 |
2018-11-28 |
昭和電工株式会社 |
レドックスフロー電池の運転方法
|
|
JP7165717B2
(ja)
|
2017-03-15 |
2022-11-04 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的免疫寛容
|
|
EP4201953A1
(en)
|
2017-04-03 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR102294136B1
(ko)
*
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
항-lag3 항체
|
|
US20210095029A1
(en)
*
|
2017-04-19 |
2021-04-01 |
University Of Southern California |
Compositions and methods for treating cancer
|
|
AU2018258045B2
(en)
|
2017-04-26 |
2024-02-29 |
Eureka Therapeutics, Inc. |
Chimeric antibody/T-cell receptor constructs and uses thereof
|
|
WO2018204303A1
(en)
*
|
2017-05-01 |
2018-11-08 |
The Children's Medical Center Coporation |
Methods and compositions relating to anti-pd1 antibody reagents
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
EA202090005A1
(ru)
*
|
2017-07-06 |
2020-06-18 |
Мерус Н.В. |
Антитела, модулирующие биологическую активность, проявляемую клеткой
|
|
US11884934B2
(en)
*
|
2017-07-21 |
2024-01-30 |
Washington University |
Methods and compositions for T cell activation
|
|
MX2020004572A
(es)
|
2017-11-01 |
2020-10-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019152743A1
(en)
*
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
SG11202007697VA
(en)
|
2018-02-15 |
2020-09-29 |
Memorial Sloan Kettering Cancer Center |
Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
|
|
TWI708787B
(zh)
|
2018-03-02 |
2020-11-01 |
美商美國禮來大藥廠 |
Pd-1促效劑抗體及其用途
|
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
CN112673093A
(zh)
*
|
2018-07-04 |
2021-04-16 |
赛通免疫治疗公司 |
靶向flt3、pd-1和/或pd-l1的免疫疗法的组合物和方法
|
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
CN111320690B
(zh)
*
|
2018-12-17 |
2022-04-05 |
程联胜 |
一种抗人Tim3单克隆抗体及其应用
|
|
CN111748580B
(zh)
*
|
2019-03-28 |
2022-09-13 |
百奥泰生物制药股份有限公司 |
一种检测免疫检查点抗体活性的方法
|
|
CN111892655B
(zh)
*
|
2019-05-06 |
2022-10-28 |
四川大学 |
抗pd-1纳米抗体的筛选及应用
|
|
CA3141327A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Operations, Inc. |
Madcam targeted immunotolerance
|
|
JP7680967B2
(ja)
*
|
2019-06-14 |
2025-05-21 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｐｄ－１に対する抗体およびその使用方法
|
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
|
EP3996735A4
(en)
*
|
2019-07-12 |
2023-07-19 |
The Research Foundation for The State University of New York |
COMPOSITIONS AND METHODS FOR BLOCKING AND BINDING CXCR4 TO MODULATE CELLULAR FUNCTION
|
|
TW202120550A
(zh)
|
2019-08-08 |
2021-06-01 |
日商小野藥品工業股份有限公司 |
雙特異性蛋白質
|
|
CA3147837A1
(en)
*
|
2019-08-16 |
2021-02-25 |
Marco Davila |
Anti-cd83 chimeric antigen receptor expressing t regulatory cells
|
|
CN112852740A
(zh)
*
|
2019-11-27 |
2021-05-28 |
深圳市菲鹏生物治疗股份有限公司 |
Car-t细胞和检测方法
|
|
EP4071172A4
(en)
|
2019-12-23 |
2023-10-18 |
Lg Chem, Ltd. |
ANTI-LILRB1 ANTIBODIES AND ITS USES
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
MA59827B1
(fr)
|
2020-05-26 |
2024-10-31 |
Boehringer Ingelheim International Gmbh |
Anticorps anti-pd-1
|
|
CN114437229B
(zh)
*
|
2020-11-01 |
2024-03-12 |
复旦大学 |
携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途
|
|
CN112812174A
(zh)
*
|
2021-01-15 |
2021-05-18 |
新乡学院 |
猪pd-l14qn-af表位多肽及其应用
|
|
CN115521378B
(zh)
*
|
2021-07-23 |
2023-12-22 |
南京吉盛澳玛生物医药有限公司 |
Pd-l1抗体及其用途
|
|
WO2024182754A2
(en)
*
|
2023-03-02 |
2024-09-06 |
Fred Hutchinson Cancer Center |
Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025085538A1
(en)
*
|
2023-10-17 |
2025-04-24 |
Lanier Biotherapeutics, Inc. |
Alarmin binding molecules and treatment of cancer
|